ANGIOGENESIS MODULATION AS AN EFFICIENT METHOD TO TREAT THE EXPERIMENTAL DIABETIC RETINOPATHY

Authors:

Abstract:

The purpose of the study was to investigate the changes in blood vascular endothelial growth factor levels in experimental animals with diabetic retinopathy modeling using the ways of its pharmacological correction. Experimental studies were performed on the model of streptozotocin-induced diabetes mellitus on Wistar rats which were randomized on seven groups in dependence of separate and combined pharmacological compounds administration to treat the experimental diabetic retinopathy features. The vascular endothelial growth factor level in the blood serum of rats was determined on 30, 60 and 180 days of the trials. The data obtained confirm the development of diabetic retinopathy in conditions of streptozotocin model of diabetes mellitus. Diabetic retinopathy development characterized by vascular endothelial growth factor content in rats blood increase with the top level of increase on the 180th day of the trials. The expressed positive effect of vascular endothelial growth factor level normalization was observed in case of aflibercept, L- arginine and citicoline combined administration. The authors stressed on immune mechanisms pathogenetic role in diabetic retinopathy. Determination of vascular endothelial growth factor principal pathogenetic role in diabetic retinal tissue damage opened a new direction of diabetic retinopathy targeted pathogenetically determined pharmacocorrection by blocking the vascular endothelial growth factor signaling pathway. The established immune mechanisms involvement into diabetic retinopathy pathogenetic mechanisms by blood vascular endothelial growth factor level increase is an experimental background of reasonability of vascular endothelial growth factor both synthesis and/or activity block in clinical conditions.

Keywords:

diabetes mellitus experimental diabetic retinopathy retinal ischemia vascular endothelial growth factor pathogenetic pharmacological correction

References:

1. Vastyanov RS, Stoyanov OM, Oleksyuk-Nekhames AH, Kalashnikov VY, Bakumenko IK, Gruzevskyi OA. et al. Kliniko-eksperymentalne obgruntuvannya patohenetychnoho likuvannya diabetychnoho urazhennya peryferychnoyi nervovoyi systemy. Medical Science of Ukraine. 2024; 20(2): 79 – 89. [In Ukrainian]. doi: https://doi.org/10.32345/2664-4738.2.2024.10.
2. Arrigo A, Aragona E, Bandello F. VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy. Ann Med. 2022; 54(1): 1089 – 1111. doi: 10.1080/07853890.2022.2064541.
3. Forrester JV, Kuffova L, Delibegovic M. The Role of Inflammation in Diabetic Retinopathy. Front Immunol. 2020; 11: 583687. doi: 10.3389/fimmu.2020.583687.
4. Forzano I, Avvisato R, Varzideh F, Jankauskas SS, Cioppa A, Mone P. et al. L-Arginine in diabetes: clinical and preclinical evidence. Cardiovascular Diabetology. 2023; 22: 89. doi: 10.1186/s12933-023-01827-2
5. Ghamdi AHA. Clinical Predictors of Diabetic Retinopathy Progression; A Systematic Review. Curr Diabetes Rev. 2020; 16(3): 242-247. doi: 10.2174/1573399815666190215120435.
6. Kang Q, Yang C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020; 37: 101799. doi: 10.1016/j.redox.2020.101799.
7. Kaštelan S, Orešković I, Bišćan F, Kaštelan H, Gverović Antunica A. Inflammatory and angiogenic biomarkers in diabetic retinopathy. Biochem Med (Zagreb). 2020; 30(3): 030502. doi: 10.11613/BM.2020.030502.
8. Lin KY, Hsih WH, Lin YB, Wen CY, Chang TJ. Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diabetes Investig. 2021; 12(8): 1322 – 1325. doi: 10.1111/jdi.13480.
9. Niklander S, Bordagaray MJ, Fernández A, Hernández M. Vascular Endothelial Growth Factor: A Translational View in Oral Non-Communicable Diseases. Biomolecules. 2021; 11(1): 85. doi: 10.3390/biom11010085.
10. Pérez-Gutiérrez L, Ferrara N. Biology and therapeutic targeting of vascular endothelial growth factor A. Nat Rev Mol Cell Biol. 2023; 24(11): 816 – 834. doi: 10.1038/s41580-023-00631-w.
11. Spencer BG, Estevez JJ, Liu E, Craig JE, Finnie JW. Pericytes, inflammation, and diabetic retinopathy. Inflammopharmacology. 2020; 28(3): 697 – 709. doi: 10.1007/s10787-019-00647-9.
12. Tan TE, Wong TY. Diabetic retinopathy: Looking forward to 2030. Front Endocrinol (Lausanne). 2023; 13: 1077669. doi: 10.3389/fendo.2022.1077669.
13. Vastyanov RS, Sadovyi OS, Stoyanov OM, Dobrovolskyi VV, Vastyanova OV, Gruzevskyi OA. Cognitive disorders expression and their pathogenetic correction in the dynamics of streptozotocin-induced diabetes. World of Medicine and Biology. 2021; 4(78): 203 – 208. doi: 10.26724/2079-8334-2021-4-78-203-208.
14. Yang J, Liu Z. Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy. Front Endocrinol (Lausanne). 2022; 13: 816400. doi: 10.3389/fendo.2022.816400.
15. Yue T, Shi Y, Luo S, Weng J, Wu Y, Zheng X. The role of inflammation in immune system of diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Front Immunol. 2022; 13: 1055087. doi: 10.3389/fimmu.2022.1055087.

Publication:

«World of Medicine and Biology» Vol. 20 No. 89 (2024) , с. 245-250
УДК 616.151.5/.153-06:616.379-008.61]-07

DOI:

https://doi.org/10.26724/2079-8334-2024-3-89-245-250